Literature DB >> 20962861

A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders.

K Yoshida, M Sanada, M Kato, R Kawahata, A Matsubara, J Takita, L-Y Shih, H Mori, H P Koeffler, S Ogawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20962861      PMCID： PMC5892825          DOI： 10.1038/leu.2010.241

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  9 in total

1.  IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Authors:  Felicitas Thol; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Frederik Damm; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Arnold Ganser; Michael Heuser
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

2.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

3.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Authors:  Masashi Sanada; Takahiro Suzuki; Lee-Yung Shih; Makoto Otsu; Motohiro Kato; Satoshi Yamazaki; Azusa Tamura; Hiroaki Honda; Mamiko Sakata-Yanagimoto; Keiki Kumano; Hideaki Oda; Tetsuya Yamagata; Junko Takita; Noriko Gotoh; Kumi Nakazaki; Norihiko Kawamata; Masafumi Onodera; Masaharu Nobuyoshi; Yasuhide Hayashi; Hiroshi Harada; Mineo Kurokawa; Shigeru Chiba; Hiraku Mori; Keiya Ozawa; Mitsuhiro Omine; Hisamaru Hirai; Hiromitsu Nakauchi; H Phillip Koeffler; Seishi Ogawa
Journal:  Nature       Date:  2009-07-20       Impact factor: 49.962

4.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

Authors:  O Kosmider; V Gelsi-Boyer; L Slama; F Dreyfus; O Beyne-Rauzy; B Quesnel; M Hunault-Berger; B Slama; N Vey; C Lacombe; E Solary; D Birnbaum; O A Bernard; M Fontenay
Journal:  Leukemia       Date:  2010-04-08       Impact factor: 12.883

7.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

8.  Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q).

Authors:  A Pardanani; M M Patnaik; T L Lasho; M Mai; R A Knudson; C Finke; R P Ketterling; R F McClure; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
  9 in total
  9 in total

1.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.

Authors:  Jumpei Yamazaki; Rodolphe Taby; Aparna Vasanthakumar; Trisha Macrae; Kelly R Ostler; Lanlan Shen; Hagop M Kantarjian; Marcos R Estecio; Jaroslav Jelinek; Lucy A Godley; Jean-Pierre J Issa
Journal:  Epigenetics       Date:  2012-02       Impact factor: 4.528

3.  Arginine CGA codons as a source of nonsense mutations: a possible role in multivariant gene expression, control of mRNA quality, and aging.

Authors:  Georgy A Romanov; Victor S Sukhoverov
Journal:  Mol Genet Genomics       Date:  2017-05-18       Impact factor: 3.291

Review 4.  Mutations in epigenetic regulators in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Bert A van der Reijden; Joop H Jansen
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

Review 5.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

6.  Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

Authors:  Tung-Liang Lin; Yasunobu Nagata; Hsiao-Wen Kao; Masashi Sanada; Yusuke Okuno; Chein-Fuang Huang; Der-Cherng Liang; Ming-Chung Kuo; Chang-Liang Lai; En-Hui Lee; Yu-Shu Shih; Hiroko Tanaka; Yuichi Shiraishi; Kenichi Chiba; Tung-Huei Lin; Jin-Hou Wu; Satoru Miyano; Seishi Ogawa; Lee-Yung Shih
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 11.047

7.  Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.

Authors:  Jie Jin; Chao Hu; Mengxia Yu; Feifei Chen; Li Ye; Xiufeng Yin; Zhengping Zhuang; Hongyan Tong
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.752

Review 8.  Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS.

Authors:  Maria Velegraki; Andrew Stiff; Helen A Papadaki; Zihai Li
Journal:  J Clin Med       Date:  2022-08-21       Impact factor: 4.964

9.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.